FMP
PNK
Inactive Equity
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody CC chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company is based in New York, New York. Regnum Corp. is a subsidiary of Phoenixus AG.
0.0001 USD
-0.0082 (-8200%)
Mr. Robert J. Stubblefield CPA
Healthcare
Biotechnology
N/A
PNK
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody CC chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company is based in New York, New York. Regnum Corp. is a subsidiary of Phoenixus AG.
0001716324
US75915R1068
75915R106
600 Third Avenue
877 313 2232
US
1
May 29, 2019